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Abstract
Background: Microalbuminuria and subsequent progression to proteinuria and nephropathy is
associated with increased oxidative stress, increased inflammatory cytokines and increased
cardiovascular (CVD) risk. The common functional IL-6 -174G>C gene variant is also associated
with elevated levels of inflammatory cytokines and CVD risk.
Methods: The aim of this study was to examine the association between the IL-6 -174G>C gene
variant with plasma total antioxidant status (TAOS) in 552 subjects with type 2 diabetes in relation
to urinary protein excretion.
Results: In subjects free from CVD, there was a significant interaction between urinary protein
excretion (normoalbuminuria/ microalbuminuria/proteinuria) and the -174C allele (compared to -
174GG) in determining plasma TAOS (p value for interaction = 0.03). In the -174C allele carriers
there was a significant association between plasma TAOS and urinary protein excretion:
normalbuminuria v microalbuminuria v proteinuria: 44.30% ± 11.32 vs. 39.74% ± 14.83 vs. 37.93%
± 16.42, ANOVA p = 0.025. In those with CVD, no interaction or association was observed with
the -174C allele (p = 0.246).
Conclusion: The IL-6 -174G>C gene variant is associated with differences in plasma oxidative
stress in response to altered protein excretion in subjects with type 2 diabetes.
Background
Interleukin-6 (IL-6) is a multifunctional inflammatory
cytokine expressed in many tissues [1,2]. The IL-6 -
174G>C functional gene variant has previously been stud-
ied in relation to the risk of coronary heart disease (CHD)
[3], juvenile onset chronic arthritis [4] and primary
Sjogren's syndrome [5]. The promoter region of this gene
contains many functional sites including a multiple
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response element (-173 to -145), which is responsive to
interleukin-1, tumour necrosis factor-α, nuclear factor-κB
(NFκ-B) and glucocorticoids [6]. In addition there is a var-
iable run of A and T bases (-257 to -276) which may affect
promoter strength [4,6]. Increased IL-6 is associated with
numerous adverse effects on the cardiovascular system,
including increased synthesis of reactive oxygen species
(ROS) via NADPH oxidase [7], and hence increased oxi-
dative stress. Previous studies have shown the -174C allele
to be associated with prospective CHD risk and hyperten-
sion [3], and in an environment of increased stress is asso-
ciated with elevated plasma IL-6 levels [8,9].
Microalbuminuria is a marker of vascular dysfunction in
subjects with type 2 diabetes mellitus (Type 2 DM), how-
ever whether it plays a causal role in cardiovascular dis-
ease (CVD) remains to be clarified [10-12].
Microalbuminuria and subsequent progression to pro-
teinuria and nephropathy is associated with increased oxi-
dative stress [13], inflammatory cytokines [14] and
increased CVD risk [12]. Previous studies have also shown
that functional gene variants in the IL-6 gene may influ-
ence progression from microalbuminuria to overt pro-
teinuria and subsequent renal failure [15], where CVD is
the major cause of mortality [16]. In vitro studies have
shown that IL-6 stimulates mesangial cell proliferation
and matrix production, two of the core features of diabetic
glomerulosclerosis [17,18]. Moreover, urinary levels of IL-
6 are elevated in patients with diabetic nephropathy [19].
Therefore IL-6, urinary protein excretion and oxidative
stress appear to be closely associated in their common
outcome of CVD and within this cluster of phenotypes
there may be important genotypic-phenotypic (gene-envi-
ronment) interactions. From the above studies we would
hypothesis that the -174C allele would be associated with
higher oxidative stress and to modulate urine protein
excretion. The aim of this study was to examine the asso-
ciation and potential interaction between the IL-6 -
174G>C functional gene variant and urinary protein
excretion, with oxidative stress in subjects with Type 2
DM. Since oxidative stress is increased in the presence of
atherosclerosis [7], we reasoned that it would also be
essential to study the association after grouping the sub-
jects by CVD status.
Methods
Subject population
Patients were recruited from the University College Diabe-
tes and Cardiovascular Study (UDACS). This comprises of
1020 consecutive subjects recruited from the diabetes
clinic at University College London Hospitals NHS Trust
(UCLH) between the years 2001–2. All patients had dia-
betes according to WHO criteria [20]. No subjects requir-
ing renal dialysis were recruited. Analyses was confined to
Caucasian subjects with Type 2 DM (605, of whom 569
were successfully genotyped for the IL-6 -174G>C gene
variant and 552 had plasma total antioxidant status
(TAOS) and urine protein excretion measured). Analysis
was therefore confined to 552 subjects. Ethical approval
was obtained from UCL/UCLH ethics committee.
Identification and classification of endpoints
Microalbuminuria was defined as an albumin:creatinine
ratio (ACR) of greater than 2.5 mg/mmol in men and 3.5
mg/mmol in women. Proteinuria was defined as an ACR
> 30 mg/mmol.
Subjects were categorised by the presence/absence of clin-
ically manifest CVD. CVD was recorded if a patient had
one or more of CHD, peripheral vascular disease (PVD) or
cerebrovascular disease (CbVD). The presence of CHD
was recorded if any patient had positive coronary angiog-
raphy or angioplasty, coronary artery bypass, a positive
cardiac thallium scan or exercise tolerance test, docu-
mented evidence of myocardial infarction or sympto-
matic/treated angina. The presence of PVD was recorded
in any patient with absent peripheral pulses and abnor-
mal lower limb doppler pressures or an abnormal lower
limb angiogram, previous angioplasty or limb by-pass
graft. CbVD was recorded if a patient had been investi-
gated for symptoms or signs consistent with a cerebrovas-
cular accident and had a brain CT showing any evidence
of infarction (diffuse/localised) or haemorrhage. Those
with either CHD or PVD or CbVD were designated as hav-
ing CVD. Subjects who were asymptomatic for CHD/
CbVD/PVD or had negative investigations were catego-
rised as having no CVD.
Measurement of plasma TAOS
Plasma TAOS was measured by a photometric microassay
previously described by Sampson et al [21]. The TAOS of
plasma was determined by its capacity to inhibit the per-
oxidase-mediated formation of the 2,2-azino-bis-3-ethyl-
bensthiazoline-6-sulfonic acid (ABTS+) radical. In the
assay, the relative inhibition of ABTS+ formation in the
presence of plasma is proportional to the antioxidant
capacity of the sample. Therefore, there are two arms to
the assay, a control arm and test arm. In the control arm
phosphate buffered saline (PBS) is used instead of
plasma. The assay is performed in a 96 well ELISA plate
using 2.5 µl of plasma. The difference in absorbance (con-
trol absorbance minus test absorbance) divided by the
control absorbance (expressed as a percentage) was used
to represent the percentage inhibition of the reaction.
Plasma TAOS is therefore inversely related to oxidative
stress (the higher the oxidative stress, the lower the
TAOS). The inter assay coefficient of variation (CV) was
14.1%, and the intra assay CV was 4.3%.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/2
Page 3 of 6
(page number not for citation purposes)
IL-6 -174G>C genotyping
Genomic leukocyte DNA was extracted by salting out
from 5 ml EDTA blood samples. Genotypes were deter-
mined using polymerase chain reaction amplification
(PCR) with published primers and conditions [3,22].
Digest products were resolved by micro-titre array diago-
nal gel electrophoresis (MADGE) [23] and confirmed by
two independent technicians blind to subject outcome,
with discrepancies resolved by repeat genotyping.
Statistical analysis
Analysis was performed using SPSS (version 10.1, SPSS
Inc., Chicago). Data are reported for those individuals
amongst whom high-throughput genotyping, plasma
TAOS and urine protein excretion measurement was suc-
cessful. Results are presented as mean ± standard devia-
tion or median (interquartile range). Deviations from
Hardy-Weinberg equilibrium were considered using chi-
squared tests. Deviations from Hardy-Weinberg equilib-
rium were considered using chi-squared tests. Hardy-
Weinberg equilibrium gives the expected genotype distri-
bution based on the observed frequency of the rare allele
(q) and common allele (p) as p2+2pq+q2, where p2 is the
predicted frequency for homozygosity of the common
allele, q2 is the predicted frequency for homozygosity of
the rare allele and 2pq, the heterozygotes. These frequen-
cies are expected provided the sample is drawn from a
population with random mating and no strong selection.
Deviations from the expected frequencies may suggest
selection bias.
Allele frequencies are shown with the 95% confidence
interval. To assess the differences between CVD and no
CVD patients, two-sided T-tests were performed on nor-
mally distributed data or after appropriate transformation
(log or square root). Analysis of variance (ANOVA) was
used to assess the association between genotypes /urinary
protein excretion and plasma TAOS, followed by a com-
parison made after combining the GC and CC groups as
the C allele has previously been shown to have a domi-
nant effect on CVD risk [3,9,24] and plasma IL-6 [8]. This
provided an ANOVA p-value between groups and a p-
value for the linear relationship between groups. The rela-
tionships between baseline parameters and plasma TAOS
were tested by Spearman rank correlation co-efficient. An
ANOVA was also performed to test the association
between genotype and TAOS after adjustment for the
potential confounders using multiple regression analysis
to obtain a residual. For the analysis of the combined
effect of genotype and urinary protein excretion on
plasma TAOS, subjects were grouped by genotype (GG
and GC/CC). ANOVA was then performed separately
within each genotype group with urinary protein excre-
tion (normoalbuminuria/ microalbuminuria/proteinu-
ria) as the independent and plasma TAOS as the
dependent variable. The interaction between genotype
and urinary protein excretion in determining plasma
TAOS was performed using linear regression were the
combined effects were compared to the individual effects
of these variables. In all cases a P value of less than 0.05
was considered statistically significant.
Results
The baseline characteristics of the subjects grouped by
CVD status are summarized in table 1. Of the 552 sub-
jects, 188 had CVD (141 CHD, 45 PVD and 37 CbVD)
and 364 no CVD. The genotype distribution was in Hardy-
Weinberg equilibrium (χ2 = 0.019, p = 0.998) with a G
allele frequency of 0.652 [0.62–0.68] and C allele fre-
quency of 0.348 [0.32–0.38]. In the whole group, no sig-
nificant association was seen between genotype and
plasma TAOS (GG: 42.26% [13.20] v GC: 41.91% [13.15]
v CC: 43.39% [13.70], ANOVA p = 0.720), and urinary
protein excretion (normoalbuminuria/microalbuminu-
ria/proteinuria p = 0.558) and CVD status, p = 0.985.
Plasma TAOS was independent of pharmacotherapy, but
correlated positively with plasma HDL-cholesterol, and
negatively with triglyceride, glucose and HbA1c (correla-
tion co-efficient r = 0.12, -0.15, -0.11 and -0.10 respec-
tively; all P < 0.05). After adjustment for these variables,
the above results remained unchanged (for genotype and
plasma TAOS, p = 0.704). No association was observed
between genotype and baseline lipid measures, blood
pressure, C-reactive protein and modes of therapy (anti-
hypertensive, oral hypoglycaemic, statin and aspirin).
Subjects without CVD
In subjects without CVD, no association was seen between
genotype and plasma TAOS (GG: 43.23% [12.40] v GC
41.79% [13.30] v CC 42.59% [14.14], ANOVA p = 0.614,
after adjustment p = 0.645) or between urinary protein
excretion and TAOS (normoalbuminuria 43.55% [11.92]
v microalbuminuria 41.54% [14.03] v proteinuria
40.00% [14.82], ANOVA p = 0.194, after adjustment p =
0.284). However in those with the -174C allele, as shown
in figure 1, there was a significant association between
higher urinary protein excretion and lower plasma TAOS
(ANOVA p = 0.025, linearity between groups, p = 0.008).
This remained significant after adjustment for age, triglyc-
eride, HDL-C, glucose and HbA1c (ANOVA p = 0.031). No
such differences were observed in those subjects
homozygous for the -174G allele. The interaction
between urinary protein excretion and genotype on
plasma TAOS was statistically significant, p = 0.032 (after
adjustment p = 0.029).
When subjects with normoalbuminuria were compared to
those with microalbuminuria and/or proteinuria, the -
174C allele was still associated with variation in plasmaCardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/2
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TAOS (p interaction = 0.02, after adjustment p = 0.016).
When subjects with frank proteinuria were excluded from
the analysis, those subjects with the -174C allele and
microalbuminuria still had the lowest plasma TAOS (p
value for interaction = 0.01, after adjustment p = 0.023).
Subjects with CVD
In subjects with CVD, no association was seen between
genotype and plasma TAOS (GG: 40.39% [14.50] v GC
42.37% [12.84] v CC 44.91% [12.98], ANOVA p = 0.332,
after adjustment p = 0.319) or between urinary protein
excretion and TAOS (normoalbuminuria 42.73% [12.84]
v microalbuminuria 41.84% [13.53] v proteinuria
39.36% [15.87], ANOVA p = 0.510, after adjustment p =
0.615). In contrast to those without CVD, no interaction
was seen between genotype and urinary protein excretion
or plasma TAOS by genotype (p = 0.246, after adjustment
p = 0.303).
Conclusion
Although there was no overall significant influence of the
IL-6 -174G>C variant on plasma TAOS or on urinary pro-
tein excretion, this study provides evidence of an impact
of this common variant in the IL-6 gene, on the relation-
ships between an intermediate phenotype (urinary pro-
tein excretion) and oxidative stress. Carriage of the -174C
allele increased the likelihood of a nephropathy-associ-
ated increase in oxidative stress in subjects with Type 2
DM. This effect was confined to subjects free from clini-
cally manifest CVD and no such interaction was observed
in those subjects with CVD. This may be explained by the
fact that in the presence of established CVD, ROS forma-
tion is increased as a result of the atherosclerotic process
[7] and this overwhelms the modest effect of genotype.
Plasma TAOS was not however significantly different
between subjects with and without CVD in our study, pos-
sibly due to the fact that those with CVD are being treated
Table 1: Baseline differences in subjects by CVD status
Trait No CVD (n = 364) CVD (n = 188) P Value
Age (years) 65.5 (11.3) 69.6 (9.6) <0.001
Duration (years)+ 8 (4–15) 10 (5.5–17) 0.008
Systolic blood pressure (mmHg)* 141 (128–153) 139 (129–154) 0.340
Diastolic blood pressure (mmHg)* 81 (74–87) 76 (71–83) 0.004
Body mass index (kg/m2)* 29.17 (26.23–32.58) 29.08 (26.13–31.97) 0.262
HbA1c (%)* 7.6 (6.6–8.9) 7.4 (6.5–8.7) 0.336
Creatinine (mmol/l)* 88 (76–103) 99 (84–122) <0.001
CRP (mg/l)*; 1.73 (1.06–3.18) 1.80 (0.99–3.34) 0.578
TAOS 42.50 (13.01) 41.83 (13.61) 0.578
Sex (F/M) 165/199 (45.3/54.7%) 57/131 (30.5/69.5%) 0.001
Normo/micro/proteinuria 201/128/35 (55.2/35.3/9.5%) 83/75/30 (44.1/39.9/16.0%) 0.019
Genotype distribution 155/165/44 (42.6/45.3/12.1%) 80/85/23 (42.6/45.2/12.2%) 0.999
ACEI (No/Yes) 197/167 (54.0/46.0%) 79/109 (42/58%) 0.008
Aspirin (No/Yes) 215/149 (59.2/40.8%) 50/138 (26.7/73.3%) <0.001
Insulin (No/Yes) 280/84 (76.8/23.2%) 130/58 (69.1/30.9%) 0.052
Statin (No/Yes) 289/75 (79.3/20.7%) 85/103 (45.2/54.8%) <0.001
Mean (SD) or Median (Interquartile range) shown, *Log transformed, +Square root transformed. Analysis performed by two-sided T-tests after 
appropriate transformation. χ2 test were used to compare groups.
Table 2: Genotype distribution by CVD status and urinary protein excretion
-174G>C genotype No CVD CVD
Normoalbumiuria Microalbuminuria Proteinuria Normoalbumiuria Microalbuminuria Proteinuria
GG 91 (25.0%) 50 (13.7%) 14 (3.8%) 35 (18.6%) 31 (16.5%) 14 (7.4%)
GC 89 (24.5%) 58 (15.9%) 18 (4.9%) 41 (21.8%) 33 (17.6%) 11 (5.9%)
CC 21 (5.8%) 20 (5.5%) 3 (0.8%) 7 (3.7%) 11 (5.9%) 5 (2.7%)
C allele frequency 0.326 (0.28–0.37) 0.383 (0.32–0.44) 0.343 (0.23–0.45) 0.331 (0.26–0.40) 0.367 (0.29–0.44) 0.350 (0.23–0.47)
The percentage in brackets is the percentage of the subject in each cell with respect to CVD/No CVD. The -174C allele frequency is shown with 
the 95% confidence interval in brackets.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/2
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with agents such as statins and aspirin, which may be
overwhelming the genotype effect.
The -174C allele has been associated with increased
plasma IL-6 under conditions of stress and with CHD risk
[3,8,9]. High levels of plasma IL-6 have also been shown
to be an independent predictor of mortality in patients
with renal impairment, prior to starting dialysis treatment
[25]. We did not observe a decrease in plasma TAOS
associated with the -174C allele, but rather an interaction
with urinary protein excretion.
Glomerular basement thickening, increased accumula-
tion of extracellular matrix and expanded mesangium are
common features of diabetic nephropathy [17,18]. Previ-
ous in vitro studies have shown that IL-6 may stimulate
mesangial cell proliferation. High levels of urinary IL-6
have also been noted in patients with diabetic nephropa-
thy [19]. As described, increased oxidative stress and CVD
risk is associated with nephropathy, renal failure [12] and
elevated plasma IL-6. Therefore in a patient with the -
174C allele and early/established nephropathy, the addi-
tive effects may be to increase plasma IL-6 and subsequent
ROS generation. Interestingly, ROS may also promote IL-
6 gene expression by activating the NFκ-B binding site,
100 base pairs downstream from the -174G>C variant
[26].
This study provides an example of a genotypic-phenotypic
(gene-environment) interaction. 'Genotype-phenotype
interaction' implies that in combination, the risk associ-
ated with a particular gene variant in a particular environ-
ment is more than the effects of each independently. From
a mechanistic viewpoint, interaction suggests that at the
molecular level, the effect or by product of the phenotypic
insult modifies the molecular function of the gene prod-
uct under observation or vice-versa. In this study we pro-
vide evidence that a common gene variant in the IL-6 -174
gene increases the likelihood of a nephropathy-associated
increase in oxidative stress in subjects with Type 2 DM.
The study of common 'genotype-phenotype' or 'gene-
environment interactions' not only provides a useful
means to improve our understanding of disease at the
molecular level but also allows specific targeting of advice
and therapies to high risk individuals (those with high-
risk genotype in a high-risk environment). From the
results described, this might involve targeting microalbu-
minuria and proteinuria more aggressively in those
patients who carry the -174C allele, for example with anti-
inflammatory agents.
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CVD = Cardiovascular disease
CHD = Coronary heart disease
PVD = Peripheral vascular disease
CbVD = Cerebrovascular disease
TAOS = Total antioxidant status
IL-6 = Interleukin-6
Plasma TAOS by genotype and urinary protein excretion in  subjects free from CVD Figure 1
Plasma TAOS by genotype and urinary protein excretion in 
subjects free from CVD. Footnote: Mean (± standard error) 
shown. Numbers of subjects are shown at the base of each 
column. In those without CVD, the interaction between gen-
otype (GG v GC/CC) and urinary protein excretion in deter-
mining plasma TAOS was significant (p = 0.032). *In the GC/
CC subjects, there was a significant difference in plasma 
TAOS by urinary protein excretion (normoalbuminuria/ 
microalbuminuria/proteinuria), ANOVA between groups p = 
0.025 (as expected the linear association in TAOS between 
these groups was significant p = 0.008 with normoalbuminu-
ric subjects having the highest TAOS and those with pro-
teinuria the lowest). In GG Subjects no such difference was 
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Type 2 DM = Type 2 diabetes
ANOVA = Analysis of variance
UDACS = University College London diabetes and cardi-
ovascular disease study
UCL = University College London
WHO = World Health Organisation
CV = Co-efficient of variation
MADGE = Microtitre array diagonal gel electrophoresis
ROS = Reactive oxygen species
CRP = C-reactive protein
ACEI = Angiotensin converting-1 enzyme inhibitor
HbA1c = Glycated haemoglobin
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